2024

Domingo, E. et al. (2024) Prognostic and predictive value of Immunoscore in stage III colorectal cancer: pooled analysis of 2,608 cases from the SCOT and IDEA-HORG studies. Journal of Clinical Oncology, (doi: 10.1200/JCO.23.01648) (PMID:38484206) (Early Online Publication)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

Frei, A. L. et al. (2024) Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: A retrospective analysis. Lancet Oncology, 25(2), pp. 198-211. (doi: 10.1016/S1470-2045(23)00560-0) (PMID:38301689)

Derby, S. et al. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641) (In Press)

2023

Lemanska, A., Harkin, A., Iveson, T., Kelly, C. , Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8(6), 102063. (doi: 10.1016/j.esmoop.2023.102063) (PMID:37988949) (PMCID:PMC10774973)

Ferguson, J. et al. (2023) Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): Protocol of a prospective, multicentre, observational study. BMJ Open Respiratory Research, 10, e001771. (doi: 10.1136/bmjresp-2023-001771) (PMID:37996118) (PMCID:PMC10668291)

Frei, A. L. et al. (2023) Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. Journal of Pathology: Clinical Research, 9(6), pp. 449-463. (doi: 10.1002/cjp2.342) (PMID:37697694) (PMCID:PMC10556275)

Corbaux, P. et al. (2023) Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. European Journal of Cancer, 191, 112966. (doi: 10.1016/j.ejca.2023.112966) (PMID:37542936)

Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)

Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)

Gallois, C. et al. (2023) Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials. Journal of Clinical Oncology, 41(4), pp. 803-815. (doi: 10.1200/JCO.21.02726) (PMID:36306483)

Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35(2), e227-e234. (doi: 10.1016/j.clon.2022.11.018) (PMID:36528474) (PMCID:PMC9708615)

2021

Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)

Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)

Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)

2020

Tsim, S., Cowell, G. W. , Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

2019

Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)

2018

Fallon, M. T., Wilcock, A., Kelly, C. A. , Paul, J. , Lewsley, L.-A., Norrie, J. and Laird, B. J.A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncology, 4(6), pp. 870-872. (doi: 10.1001/jamaoncol.2018.0131) (PMID:29621378) (PMCID:PMC6145686)

Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)

Ashton, M. et al. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)

2017

Paul, J. , Kelly, C. , Stobo, J. and Powles, T. (2017) Reply to M. Horiguchi et al. Journal of Clinical Oncology, 35(29), pp. 3373-3374. (doi: 10.1200/jco.2017.74.4292) (PMID:28800270)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)

Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)

2016

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

MacLeod, N., Kelly, C. , Stobo, J. , McMahon, L., Taggart, D., Fallon, M. and Laird, B. J. (2016) Pain in malignant pleural mesothelioma: a prospective characterization study. Pain Medicine, 17(11), pp. 2119-2126. (doi: 10.1093/pm/pnw061) (PMID:27117437)

2015

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi: 10.17795/rro-3999)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi: 10.1097/JTO.0000000000000499) (PMID:25654216)

2014

Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)

Aitchison, M., Bray, C.A. , Van Poppel, H., Sylvester, R., Graham, J., Innes, C., McMahon, L. and Vasey, P.A. (2014) Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. European Journal of Cancer, 50(1), pp. 70-77. (doi: 10.1016/j.ejca.2013.08.019) (PMID:24074763)

2012

Partridge, M., Fallon, M., Bray, C., McMillan, D. , Brown, D. and Laird, B. (2012) Prognostication in advanced cancer: a study examining an inflammation-based score. Journal of Pain and Symptom Management, 44(2), pp. 161-167. (doi: 10.1016/j.jpainsymman.2011.08.013)

2010

Robertson, G., Greenlaw, N. , Bray, C. and Morrison, D. (2010) Explaining the effects of socio-economic deprivation on survival in a national prospective cohort study of 1909 patients with head and neck cancers. Cancer Epidemiology, 34(6), pp. 682-688.

2008

Bray, C.A., Morrison, D.S. and McKay, P. (2008) Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland. Leukemia and Lymphoma, 49(5), pp. 917-923.

Whiteman, D.C., Bray, C.A., Siskind, V., Green, A.C., Hole, D.J. and Mackie, R.M. (2008) Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? European Journal of Cancer Prevention, 17(3), pp. 243-250. (doi: 10.1097/CEJ.0b013e3282b6fe3f)

2007

Mackie, R. M., Bray, C., Vestey, J., Doherty, V., Evans, A., Thomson, D. and Nicolson, M. (2007) Melanoma incidence and mortality in Scotland 1979–2003. British Journal of Cancer, 96(11), pp. 1772-1777. (doi: 10.1038/sj.bjc.6603801)

Whiteman, D.C., Bray, C.A., Siskind, V., Hole, D., Mackie, R.M. and Green, A.C. (2007) A comparison of the anatomic distribution of cutaneous melanoma in two populations with different levels of sunlight: the west of Scotland and Queensland, Australia 1982–2001. Cancer Causes and Control, 18(5), pp. 485-491. (doi: 10.1007/s10552-007-0123-1)

2006

Kettlewell, S., Moyes, C., Bray, C., Soutar, D., MacKay, A., Byrne, D., Shoaib, T., Majumder, B. and MacKie, R. (2006) Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. British Medical Journal, 332, p. 1423. (doi: 10.1136/bmj.38849.680509)

2004

MacKie, R. and Bray, C.A. (2004) Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. British Journal of Cancer, 90(4), pp. 770-772. (doi: 10.1038/sj.bjc.6601595)

2003

Mackie, R.M., Bray, C.A. and Leman, J.A. (2003) Effect of public education aimed at early diagnosis of malignant melanoma: cohort comparison study. British Medical Journal, 326, p. 367. (doi: 10.1136/bmj.326.7385.367)

2002

Mackie, R.M., Bray, C.A. and Hole, D.J. (2002) Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma. British Medical Journal, 325, pp. 1276-1277. (doi: 10.1136/bmj.325.7375.1276)

Mackie, R.M., Bray, C.A., Hole, D.J., Morris, A., Nicolson, M., Evans, A., Doherty, V. and Vestey, J. (2002) Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet, 360(9333), pp. 587-591. (doi: 10.1016/S0140-6736(02)09779-9)

1998

MacLeod, M.C.M., Bray, C.A., Kendrick, S.W. and Cobbe, S.M. (1998) Enhancing the power of record linkage involving low quality personal identifiers: use of the best link principle and cause of death prior likelihoods. Computers and Biomedical Research, 31(4), pp. 257-270. (doi: 10.1006/cbmr.1998.1480)

Articles

Domingo, E. et al. (2024) Prognostic and predictive value of Immunoscore in stage III colorectal cancer: pooled analysis of 2,608 cases from the SCOT and IDEA-HORG studies. Journal of Clinical Oncology, (doi: 10.1200/JCO.23.01648) (PMID:38484206) (Early Online Publication)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

Frei, A. L. et al. (2024) Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: A retrospective analysis. Lancet Oncology, 25(2), pp. 198-211. (doi: 10.1016/S1470-2045(23)00560-0) (PMID:38301689)

Derby, S. et al. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, (doi: 10.1016/j.ijrobp.2024.01.011) (PMID:38211641) (In Press)

Lemanska, A., Harkin, A., Iveson, T., Kelly, C. , Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8(6), 102063. (doi: 10.1016/j.esmoop.2023.102063) (PMID:37988949) (PMCID:PMC10774973)

Ferguson, J. et al. (2023) Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): Protocol of a prospective, multicentre, observational study. BMJ Open Respiratory Research, 10, e001771. (doi: 10.1136/bmjresp-2023-001771) (PMID:37996118) (PMCID:PMC10668291)

Frei, A. L. et al. (2023) Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. Journal of Pathology: Clinical Research, 9(6), pp. 449-463. (doi: 10.1002/cjp2.342) (PMID:37697694) (PMCID:PMC10556275)

Corbaux, P. et al. (2023) Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. European Journal of Cancer, 191, 112966. (doi: 10.1016/j.ejca.2023.112966) (PMID:37542936)

Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)

Karamouza, E. et al. (2023) CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data. Cancers, 15(6), 1823. (doi: 10.3390/cancers15061823) (PMID:36980708) (PMCID:PMC10047009)

Gallois, C. et al. (2023) Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials. Journal of Clinical Oncology, 41(4), pp. 803-815. (doi: 10.1200/JCO.21.02726) (PMID:36306483)

Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35(2), e227-e234. (doi: 10.1016/j.clon.2022.11.018) (PMID:36528474) (PMCID:PMC9708615)

Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)

Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)

Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)

Tsim, S., Cowell, G. W. , Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)

Fallon, M. T., Wilcock, A., Kelly, C. A. , Paul, J. , Lewsley, L.-A., Norrie, J. and Laird, B. J.A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncology, 4(6), pp. 870-872. (doi: 10.1001/jamaoncol.2018.0131) (PMID:29621378) (PMCID:PMC6145686)

Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)

Ashton, M. et al. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

Paul, J. , Kelly, C. , Stobo, J. and Powles, T. (2017) Reply to M. Horiguchi et al. Journal of Clinical Oncology, 35(29), pp. 3373-3374. (doi: 10.1200/jco.2017.74.4292) (PMID:28800270)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)

Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

MacLeod, N., Kelly, C. , Stobo, J. , McMahon, L., Taggart, D., Fallon, M. and Laird, B. J. (2016) Pain in malignant pleural mesothelioma: a prospective characterization study. Pain Medicine, 17(11), pp. 2119-2126. (doi: 10.1093/pm/pnw061) (PMID:27117437)

Mac Leod, N. et al. (2015) F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study. Reports of Radiotherapy and Oncology, 2(2), e3999. (doi: 10.17795/rro-3999)

MacLeod, N. et al. (2015) Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. Journal of Thoracic Oncology, 10(6), pp. 944-950. (doi: 10.1097/JTO.0000000000000499) (PMID:25654216)

Macpherson, I.R., Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi: 10.1016/j.clbc.2014.09.009) (PMID:25454689)

Aitchison, M., Bray, C.A. , Van Poppel, H., Sylvester, R., Graham, J., Innes, C., McMahon, L. and Vasey, P.A. (2014) Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. European Journal of Cancer, 50(1), pp. 70-77. (doi: 10.1016/j.ejca.2013.08.019) (PMID:24074763)

Partridge, M., Fallon, M., Bray, C., McMillan, D. , Brown, D. and Laird, B. (2012) Prognostication in advanced cancer: a study examining an inflammation-based score. Journal of Pain and Symptom Management, 44(2), pp. 161-167. (doi: 10.1016/j.jpainsymman.2011.08.013)

Robertson, G., Greenlaw, N. , Bray, C. and Morrison, D. (2010) Explaining the effects of socio-economic deprivation on survival in a national prospective cohort study of 1909 patients with head and neck cancers. Cancer Epidemiology, 34(6), pp. 682-688.

Bray, C.A., Morrison, D.S. and McKay, P. (2008) Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland. Leukemia and Lymphoma, 49(5), pp. 917-923.

Whiteman, D.C., Bray, C.A., Siskind, V., Green, A.C., Hole, D.J. and Mackie, R.M. (2008) Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? European Journal of Cancer Prevention, 17(3), pp. 243-250. (doi: 10.1097/CEJ.0b013e3282b6fe3f)

Mackie, R. M., Bray, C., Vestey, J., Doherty, V., Evans, A., Thomson, D. and Nicolson, M. (2007) Melanoma incidence and mortality in Scotland 1979–2003. British Journal of Cancer, 96(11), pp. 1772-1777. (doi: 10.1038/sj.bjc.6603801)

Whiteman, D.C., Bray, C.A., Siskind, V., Hole, D., Mackie, R.M. and Green, A.C. (2007) A comparison of the anatomic distribution of cutaneous melanoma in two populations with different levels of sunlight: the west of Scotland and Queensland, Australia 1982–2001. Cancer Causes and Control, 18(5), pp. 485-491. (doi: 10.1007/s10552-007-0123-1)

Kettlewell, S., Moyes, C., Bray, C., Soutar, D., MacKay, A., Byrne, D., Shoaib, T., Majumder, B. and MacKie, R. (2006) Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. British Medical Journal, 332, p. 1423. (doi: 10.1136/bmj.38849.680509)

MacKie, R. and Bray, C.A. (2004) Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. British Journal of Cancer, 90(4), pp. 770-772. (doi: 10.1038/sj.bjc.6601595)

Mackie, R.M., Bray, C.A. and Leman, J.A. (2003) Effect of public education aimed at early diagnosis of malignant melanoma: cohort comparison study. British Medical Journal, 326, p. 367. (doi: 10.1136/bmj.326.7385.367)

Mackie, R.M., Bray, C.A. and Hole, D.J. (2002) Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma. British Medical Journal, 325, pp. 1276-1277. (doi: 10.1136/bmj.325.7375.1276)

Mackie, R.M., Bray, C.A., Hole, D.J., Morris, A., Nicolson, M., Evans, A., Doherty, V. and Vestey, J. (2002) Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet, 360(9333), pp. 587-591. (doi: 10.1016/S0140-6736(02)09779-9)

MacLeod, M.C.M., Bray, C.A., Kendrick, S.W. and Cobbe, S.M. (1998) Enhancing the power of record linkage involving low quality personal identifiers: use of the best link principle and cause of death prior likelihoods. Computers and Biomedical Research, 31(4), pp. 257-270. (doi: 10.1006/cbmr.1998.1480)

Conference or Workshop Item

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)